as mentioned in kelownanow
Canadians to test Ebola vaccine this fall
Canadians to test Ebola vaccine this fall
The Canadian Ebola vaccine will soon enter new trial phase, meaning it's one step closer to being used.On Tuesday, the International Development Minister Marie-Claude Bibeau and Health Minister Jane Philpott announced that the next phase of clinical trials for the Ebola vaccine (VSV-EBOV), originally developed by the Public Health Agency of Canada, will begin in fall 2016."Canada is a leader on the world scientific stage, and this vaccine is example of how we can translate that knowledge into a vaccine that will ultimately protect some of the world's poorest and most vulnerable from another Ebola outbreak, as well as Canadians abroad," said Bibeau.
coupled with enca
New Ebola vaccine to be tested next month in Canada
New Ebola vaccine to be tested next month in Canada
File: A new Ebola vaccine will be tested in Canada from next month on HIV patients.Photo: AFP / Cellou BinaniOTTAWA – An Ebola vaccine developed by Canadian researchers and considered by the WHO to be the first effective treatment against the virus will soon start a new phase of clinical trials, Ottawa announced Tuesday.The vaccine's safety and effectiveness will be tested on volunteers infected with HIV, starting in Ottawa and Montreal in November, and followed by trials in Senegal and Burkina Faso next year, the government said in a statement.
in the same way scidev
New Ebola vaccine under consideration for emergency use
New Ebola vaccine under consideration for emergency use
"We are confident that we have the potential to contribute to end the Ebola problem." Johan van Hoof, Janssen Pharmaceutical Companies[ANTWERP, BELGIUM] The next Ebola outbreak could have a prime-boost vaccine available, particularly for health workers and vulnerable communities on the front-line, a conference has heard.Prime-boost vaccination involves giving an initial dose to prime the immune system, followed by a booster dose at a later date with the goal of potentially strengthening and optimising the duration of immunity."We are confident that we have the potential to contribute to end the Ebola problem," says Johan van Hoof, global therapeutic area head, infectious diseases and vaccines, Janssen Pharmaceutical Companies headquartered in Belgium.The immune system has been found to persist beyond one year, which is pretty good, van Hoof notes.Last month (12 September), big pharma Johnson & Johnson, announced that its subsidiary Janssen Vaccines & Prevention B.V, has submitted its investigational preventive Ebola prime-boost vaccine regimen to the WHO to be used in such instances.This was announced at the 8th International Symposium on Filoviruses in Antwerp, Belgium, hosted by the Antwerp Institute of Tropical Medicine, last month (12-15 September).The symposium focused on the 40-year history of Ebola."If listed for emergency use, the investigational Janssen vaccine regimen could be a vital prevention tool for rapid outbreak response," van Hoof explains.It has already been tested in animal models and for safety.The application is considered under the WHO Emergency Use Assessment and Listing (EUAL) procedure to fast-track R&D for potential Ebola diagnostics, treatments and vaccines."Over the past four decades, we have seen 25 Ebola outbreaks, with the most recent in West Africa killing seven times more people than all previous outbreaks combined," says Paul Stoffels, the chief scientific officer, Johnson & Johnson, in statement released last month (12 September).
No comments:
Post a Comment